| Bioactivity | Atorolimumab (P3x22914G4) is a monoclonal antibody used for immunotherapies targeting programmed death-1 (PD-1)[1]. |
| Name | Atorolimumab |
| CAS | 202833-08-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Oura K, et al. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2022 Dec 14;9:1279-1298. |